Oppenheimer has PT of $7/share for ALIM stock. Should we believe you, or believe Oppenheimer? LOL!
2/29/12 Oppenheimer increased its Alimera Sciences (NASDAQ: ALIM) price target from $4 to $7 in a research report published today. In the report, Oppenheimer stated, "We believe ALIM is leaning toward a commercialization partnership, which would bring in needed capital near-term. We believe ALIM is substantially undervalued on Iluvien's E.U. opportunity." Shares of Alimera Sciences closed today at $3.94 , up 70.56% from Monday's market close.